Endocrine and Metabolic Conditions Flashcards

A commercial driver holds an active FMCSA Insulin-Treated Diabetes Mellitus (ITDM) exemption. Before a scheduled long-haul trip, he checks his blood glucose and reads 97 mg/dL. Under FMCSA exemption program requirements, what is the correct course of action?

Answer: He must consume carbohydrates, wait at least 45 minutes, and recheck before driving

The FMCSA ITDM exemption program requires blood glucose to be ≥100 mg/dL before operating a CMV. A reading of 97 mg/dL falls below this threshold. The driver must treat the low glucose, wait at least 45 minutes after treatment, and confirm a reading ≥100 mg/dL before driving. The 45-minute wait ensures glucose has stabilized and rapid reversal has occurred.

During a medical history review for ITDM exemption renewal, a driver reports that over the past 4 years he has had two episodes requiring assistance from another person to treat hypoglycemia. His endocrinologist confirms 'hypoglycemia unawareness' is not present. What is the correct certification determination?

Answer: Grant exemption renewal since he remains below the three-episode threshold within 5 years

Under the FMCSA ITDM exemption program, disqualification requires three or more severe hypoglycemic episodes (requiring third-party assistance) in the preceding 5 years. This driver has had two such episodes — below the disqualifying threshold. The absence of hypoglycemia unawareness is also a positive factor. Renewal can be granted if all other exemption criteria are met.

A 44-year-old applicant is being evaluated for a commercial driver's certificate. Labs reveal a TSH of 0.08 mIU/L (low) and free T4 of 2.6 ng/dL (high). The driver reports occasional palpitations but denies syncope or near-syncope. He is not currently on any treatment. What is the correct certification action?

Answer: Disqualify until the hyperthyroid condition is treated and labs normalize

Overt, untreated hyperthyroidism (suppressed TSH with elevated free T4) is disqualifying for CMV certification because it can cause cardiac arrhythmias, tremor, heat intolerance, anxiety, and unpredictable neurological/cardiovascular events that impair safe driving. The driver must be treated and achieve euthyroid status — confirmed by normalized thyroid labs — before certification. There is no partial certification or route restriction provision for this condition.

A driver with a history of surgically resected pheochromocytoma presents for a DOT physical. The resection was 18 months ago. Postoperative 24-hour urine metanephrines and plasma-free metanephrines have been normal on three consecutive annual checks (the most recent is 6 months old). He is asymptomatic and normotensive off medication. What should the medical examiner do?

Answer: Certify for 1 year, requiring updated biochemical cure documentation at each annual exam

Pheochromocytoma is disqualifying when active due to risk of hypertensive crisis and sudden incapacitation. However, after successful surgical resection with confirmed biochemical remission (normal metanephrines), certification is possible. The FMCSA standard does not impose a permanent bar post-resection, but given the recurrence risk (up to 10–17%), annual certification with documented proof of continued biochemical remission is the appropriate cautious approach. A 2-year certificate is inappropriate given ongoing recurrence surveillance needs.

An ITDM exemption holder is 3 hours into a long-haul drive and performs the required en-route glucose check. His reading is 68 mg/dL. He feels fine and attributes it to skipping a snack. He wants to pull over, eat glucose tablets, and resume driving in 20 minutes. Why is this plan non-compliant with exemption program requirements?

Answer: He must wait at least 45 minutes after treatment and confirm blood glucose ≥100 mg/dL before resuming

When a blood glucose reading falls below 100 mg/dL during a CMV trip, ITDM exemption program requirements mandate that the driver stop driving immediately, treat the hypoglycemia, and wait a minimum of 45 minutes before rechecking. Driving may only resume if the post-treatment glucose is ≥100 mg/dL. A 20-minute wait is insufficient — glucose counterregulation and symptom resolution take time, and the driver may still be impaired even if subjectively feeling fine due to the delayed physiologic response.

A driver with Type 2 diabetes managed with metformin and a GLP-1 receptor agonist (semaglutide) presents for a DOT physical. His HbA1c is 7.1%, he has no hypoglycemic episodes in his history, and he reports nausea and occasional vomiting related to the GLP-1 agent. Funduscopic exam is normal and monofilament testing reveals intact sensation bilaterally. What is the most accurate certification determination?

Answer: Certify for up to 2 years; non-insulin antidiabetics do not require an exemption and his controlled disease meets the standard

The federal diabetes disqualification (49 CFR 391.41(b)(3)) specifically applies to drivers who use insulin for glycemic control. Non-insulin medications — including GLP-1 receptor agonists like semaglutide — do not trigger the ITDM exemption requirement. GLP-1 agonists carry minimal intrinsic hypoglycemia risk when used without insulin. This driver's HbA1c is well-controlled, he has no peripheral neuropathy or retinopathy, and no hypoglycemic history. GI side effects alone are not a federal disqualifier. He may be certified for up to 2 years under the standard examination cycle.